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In this issue, we have a thought-provoking article that relates
to managing risk in designing strategic alliances in the
biotech–pharmaceutical space. Joanne L. Scillitoe, Shanthi
Gopalakrishnan, and Michael D. Santoro investigate factors that
influence specific governance structures in strategic alliances
for the development of new medications in their article,
“The Impact of External Contexts on Alliance Governance in
Biotech–Pharmaceutical Firm Alliances.”
Scillitoe and colleagues explore a key aspect of managing
risk in innovation—the creation of governance structures in
strategic alliances. Partnerships between biotech firms and pharmaceutical companies provide each partner with the needed
skills, knowledge, and competencies to commercialize promising new drugs. But the creation of an alliance presents some
degree of risk to both partners. The success of these partnerships
depends, in part, on the governance structure of the alliance—
whether there is a presence or absence of equity involvement.
The choice of governance structure has been shown to be related
to a number of contextual factors, and in this article, the authors
explore the role of international, technological and social context in influencing the choice of structure from the perspective
of the biotech partner.

In terms of international culture, the article explores the
effect of national cultural differences, hypothesizing that greater
differences in culture between partners increases the likelihood of creating equity structures. In the context of technology,
the article hypothesizes that biotech firms situated in areas
with a greater technological knowledge base will be more
likely to form nonequity alliances with their pharma partners. And finally, the authors hypothesize that the greater
the credibility of the biotech firm, formed through social
networks, the more likely the firm is to form nonequity
alliances.
Their findings support their proposition that greater national
cultural distance increases equity alliances, but do not support
the hypothesis that firms from more technologically munificent areas are more likely to form nonequity alliances. Firms
with greater credibility were found to be more likely to engage
in nonequity arrangements. These findings provide important
insights for biotech firms, pharmaceutical firms, and the broader
study of strategic alliances. When managing risk and protecting important intellectual and technological capital, firms are
wise to consider the international and social contexts of the
relationship.
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